Welgene Biotech Co.,Ltd. (TPEX:6661)
Taiwan · Delayed Price · Currency is TWD 18.60
-0.50 (-2.62%)
At close: Feb 11, 2026
Welgene Biotech Revenue
Welgene Biotech had revenue of 110.10M TWD in the quarter ending September 30, 2025, with 21.70% growth. This brings the company's revenue in the last twelve months to 365.75M, up 18.54% year-over-year. In the year 2024, Welgene Biotech had annual revenue of 322.55M with 14.97% growth.
Revenue (ttm)
365.75M
Revenue Growth
+18.54%
P/S Ratio
1.19
Revenue / Employee
n/a
Employees
n/a
Market Cap
433.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 322.55M | 42.00M | 14.97% |
| Dec 31, 2023 | 280.55M | -41.35M | -12.85% |
| Dec 31, 2022 | 321.90M | 9.25M | 2.96% |
| Dec 31, 2021 | 312.65M | -85.45M | -21.46% |
| Dec 31, 2020 | 398.10M | -19.36M | -4.64% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| EPS Bio Technology | 497.19M |
| Health & Life | 441.84M |
| Taiwan Advanced Nanotech | 172.11M |
| Pharmigene | 149.25M |
| UniPharma | 90.79M |
| Vectorite Biomedical | 67.90M |